GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

as well as Viva, a beverage containing wheat and barley and chocolate caramel drink Maltova. Shares of GlaxoSmithKline Consumer Healthcare have advanced 9% in India's trading this year ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

BRENTFORD, Britain — BRENTFORD, Britain — GSK plc (GSK) on Wednesday reported a loss of $75.4 million in its third quarter. The Brentford, Britain-based company said it had a loss of 4 cents ...

Viva Medicare Advantage plans are available in Alabama and get slightly above-average star ratings from CMS. Many, or all, of the products featured on this page are from our advertising partners ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...